Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017 (2017), Article ID 2153629, 11 pages
https://doi.org/10.1155/2017/2153629
Research Article

Intravenous Administration of Adipose-Derived Stem Cell Protein Extracts Improves Neurological Deficits in a Rat Model of Stroke

1Department of Neurosurgery, The First Affiliate Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China
2Neuroinflammation Unit, Montreal Neurological Institute, McGill University, Montreal, QC, Canada H3A 2B4
3Department of Immunology, Harbin Medical University, Harbin, Heilongjiang 150086, China
4Department of Neurosurgery, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150001, China

Correspondence should be addressed to Hongwei Xu; moc.liamtoh@65iewgnoh and Lixian Li; moc.anis@ydhzxll

Received 5 September 2016; Revised 21 November 2016; Accepted 27 November 2016; Published 7 February 2017

Academic Editor: Marc L. Turner

Copyright © 2017 Kai Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Treatment of adipose-derived stem cell (ADSC) substantially improves the neurological deficits during stroke by reducing neuronal injury, limiting proinflammatory immune responses, and promoting neuronal repair, which makes ADSC-based therapy an attractive approach for treating stroke. However, the potential risk of tumorigenicity and low survival rate of the implanted cells limit the clinical use of ADSC. Cell-free extracts from ADSC (ADSC-E) may be a feasible approach that could overcome these limitations. Here, we aim to explore the potential usage of ADSC-E in treating rat transient middle cerebral artery occlusion (tMCAO). We demonstrated that intravenous (IV) injection of ADSC-E remarkably reduces the ischemic lesion and number of apoptotic neurons as compared to other control groups. Although ADSC and ADSC-E treatment results in a similar degree of a long-term clinical beneficial outcome, the dynamics between two ADSC-based therapies are different. While the injection of ADSC leads to a relatively mild but prolonged therapeutic effect, the administration of ADSC-E results in a fast and pronounced clinical improvement which was associated with a unique change in the molecular signature suggesting that potential mechanisms underlying different therapeutic approach may be different. Together these data provide translational evidence for using protein extracts from ADSC for treating stroke.